Equities researchers at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Price Performance
NYSE:NAVB opened at $0.00 on Tuesday. The firm has a market cap of $50,042.00, a price-to-earnings ratio of -0.01 and a beta of 0.75. The company has a 50 day moving average price of $0.03 and a 200-day moving average price of $0.04. Navidea Biopharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.15.
Navidea Biopharmaceuticals Company Profile
Featured Articles
- Five stocks we like better than Navidea Biopharmaceuticals
- What is the Shanghai Stock Exchange Composite Index?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Golden Cross Stocks: Pattern, Examples and Charts
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.